Remix Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing small molecule therapies, raised $60M in funding.
The round was led by The Column Group with participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor along with new investors WTT Investment, Willett Advisors, and others.
The company intends to use the funds to support clinical development of its lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.
Led by CEO and Ph.D. Peter Smith, Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. RNA processing is the pathway that controls gene and protein expression. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to identify and target key RNA processing steps to modulate gene expression. Its therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin.
FinSMEs
03/01/2024